Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telaglenastat - Cornerstone Pharmaceuticals

Next Previous
Drug Profile

Telaglenastat - Cornerstone Pharmaceuticals

Alternative Names: CB 839

Latest Information Update: 12 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Calithera Biosciences
  • Developer Calithera Biosciences; Case Western Reserve University; Cornerstone Pharmaceuticals Inc; M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer; Synhale Therapeutics
  • Class Acetamides; Antineoplastics; Ethers; Fluorinated hydrocarbons; Pyridazines; Pyridines; Small molecules; Thiadiazoles
  • Mechanism of Action Glutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Pulmonary hypertension
  • Preclinical Cancer; Chronic obstructive pulmonary disease
  • Discontinued Colorectal cancer; Glioma; Haematological malignancies; Leukaemia; Malignant melanoma; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 01 May 2025 Synhale Therapeutics acquires Telaglenastat from Cornerstone Pharmaceuticals
  • 01 May 2025 Clinical trials in Pulmonary hypertension (PO)
  • 01 May 2025 Synhale Terapeutics plans a phase II trial for Pulmonary hypertension

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top